Melissa McLaughlin net worth and biography

Melissa McLaughlin Biography and Net Worth

Chief Human Resources Officer of Alnylam Pharmaceuticals

Melissa McLaughlin joined Alnylam in 2025 as Chief Human Resources Officer. Melissa joins Alnylam with more than 25 years of experience in human resources leadership, talent development, and organizational culture at large, globally recognized companies, including Expedia Group, Johnson & Johnson, and The Gillette Company.

Melissa founded her own HR consulting firm, Flourish People Practices, which shapes HR strategies for biotech and technology organizations with international footprints. Melissa is an advisor for Google Ventures, where she addresses people and organizational scaling challenges for their portfolio companies. Prior to owning her own practice, Melissa spent seven years as the Chief People Officer at Agios Pharmaceuticals.

Melissa holds a bachelor’s degree in human resources management from Boston College, Carroll School of Management, and a master’s degree from INSEAD. She serves as Chair of the Board of Directors at Lumicks, a global life sciences tools company.

What is Melissa McLaughlin's net worth?: The estimated net worth of Melissa McLaughlin is at least $3.84 million as of April 2nd, 2026. Ms. McLaughlin owns 11,729 shares of Alnylam Pharmaceuticals stock worth more than $3,838,350 as of April 8th. This net worth estimate does not reflect any other assets that Ms. McLaughlin may own. Learn More about Melissa McLaughlin's net worth.
How do I contact Melissa McLaughlin?: The corporate mailing address for Ms. McLaughlin and other Alnylam Pharmaceuticals executives is 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142. Alnylam Pharmaceuticals can also be reached via phone at (617) 551-8200 and via email at [email protected]. Learn More on Melissa McLaughlin's contact information.
Has Melissa McLaughlin been buying or selling shares of Alnylam Pharmaceuticals?: During the past quarter, Melissa McLaughlin has sold $1,274,354.28 in Alnylam Pharmaceuticals stock. Most recently, Melissa Mclaughlin sold 2,286 shares of the business's stock in a transaction on Monday, April 6th. The shares were sold at an average price of $330.42, for a transaction totalling $755,340.12. Following the completion of the sale, the insider now directly owns 9,443 shares of the company's stock, valued at $3,120,156.06. Learn More on Melissa McLaughlin's trading history.
Who are Alnylam Pharmaceuticals' active insiders?: Alnylam Pharmaceuticals' insider roster includes Dennis Ausiello (Director), Michael Bonney (Director), Jeffrey Dunn (CEO), Kevin Fitzgerald (EVP), Indrani Franchini (EVP), Pushkal Garg (CMO), Yvonne Greenstreet (COO), Laurie Keating (EVP), John Maraganore (CEO), Melissa McLaughlin (Chief Human Resources Officer), Steven Paul (Director), Jeffrey Poulton (CFO), David Pyott (Director), Colleen Reitan (Director), Amy Schulman (Director), Phillip Sharp (Director), Tolga Tanguler (EVP), and Akshay Vaishnaw (Insider). Learn More on Alnylam Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Alnylam Pharmaceuticals?: In the last year, insiders at the biopharmaceutical company sold shares 41 times. They sold a total of 244,692 shares worth more than $96,139,471.95. The most recent insider tranaction occured on April, 6th when insider Melissa Mclaughlin sold 2,286 shares worth more than $755,340.12. Insiders at Alnylam Pharmaceuticals own 1.2% of the company. Learn More about insider trades at Alnylam Pharmaceuticals.
Information on this page was last updated on 4/6/2026.

Melissa McLaughlin Insider Trading History at Alnylam Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
4/6/2026	Sell	2,286	$330.42	$755,340.12	9,443
4/2/2026	Sell	1,624	$319.59	$519,014.16	11,729

Melissa McLaughlin Buying and Selling Activity at Alnylam Pharmaceuticals

Alnylam Pharmaceuticals Company Overview

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $327.25

$324.44

$330.30

50 Day Range

MA: $325.44

$306.66

$351.96

2 Week Range

Now: $327.25

$205.87

$495.55

Volume

973,356 shs

Average Volume

1,366,130 shs

Market Capitalization

$43.40 billion

P/E Ratio

191.37

Dividend Yield

N/A

Beta

0.39